Source:http://linkedlifedata.com/resource/pubmed/id/18694360
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2008-8-12
|
pubmed:abstractText |
Producing an alternative to human erythrocytes has been one the most exciting dreams of medicine. Hemoglobin-based oxygen carriers (HBOCs) derived from purified human or bovine hemoglobin have been studied for clinical use and one product is currently available in the United States and European Union for veterinary use, and another in South Africa for human use.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1744-7682
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1425-33
|
pubmed:meshHeading | |
pubmed:year |
2008
|
pubmed:articleTitle |
HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation).
|
pubmed:affiliation |
David Geffen School of Medicine at UCLA, UCLA Department of Anesthesiology, CHS 56-122, Box 951778, Los Angeles, CA 90095-1778, USA. JSJahr@mednet.ucla.edu
|
pubmed:publicationType |
Journal Article,
Review
|